Ingen Technologies Forges an Indelible Mark In the Medical World With Projected Revenues of $200 Million in the Oxygen Cannula Market

• Print

• Companies:

  • Ingen Technologies, Inc.

Related Quotes

Symbol	Price	Change
IGNT.PK	0.0005	0.0000

{"s" : "ignt.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""}

Press Release Source: Ingen Technologies, Inc. On Friday June 4, 2010, 8:15 am EDT

YUCAIPA, Calif., June 4, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT - News) the leading global medical device manufacturer of intelligent oxygen nasal cannulas focused on the $4 billion respiratory market, today announced that its innovative SMART Nasal Cannula with Oxyview technology are addressing unmet needs with an expected $200 million in revenues over the next 5 years.

Ingen has recently noticed a nice spike in sales from respiratory equipment manufacturers who require Ingen's gas flow meter technology for their own medical equipment.

Since 2007 when Ingen first introduced Oxyview to the world of COPD patients, the acceptance of the product has been impressive. There is no other product like Oxyview that provides the additional information that patients and clinicians rely upon. With approximately 23 million patients in the U.S. -- and an estimated 600 million patients worldwide -- who suffer from chronic obstructive pulmonary disease (COPD), Ingen stands to capture $200M in revenues over the next 5 years. Since an average COPD patient uses two to three nasal cannulas each month to prevent bacteria build-up within the device, creating a growing recurring demand for the cannula is an additional benefit to Ingen's bottom line.

View Fact Sheet: http://www.ingen-tech.com/PDFbin/FactSheet.pdf

Ingen's SMART Nasal Cannula is superior and very different than that of the conventional oxygen nasal cannulas on the market that now are commoditized products and mass produced overseas and offer patients very little peace-of-mind. As a result, it is not uncommon for home care providers to make frequent visits to oxygen patients concerned that oxygen is not flowing from the tank to the cannula, since there is no way to accurately verify it.

Ingen's one-of-a-kind, patented, high quality SMART Nasal Cannula solves this problem by confirming the flow of oxygen and proper equipment function at roughly the same cost as a traditional cannula. The result is lower costs for home care providers and greater peace-of-mind for in-home oxygen patients with respiratory diseases like COPD.

"Ingen's innovative oxygen cannulas are rapidly gaining traction due to their unique ability to lower costs for home care providers and provide peace-of-mind for oxygen patients," said Ingen CEO Scott Sand. "We have already booked more than $160,000 in revenues during the fourth quarter with $300,000 more in OEM orders backlogged, in addition to $1.4M in government contracts -- and we're just scratching the surface."

http://www.ingen-tech.com/

http://www.smartnasalcannula.com/

http://www.ingenpulseoximeter.com/